ABCB1 p.Phe983Ala
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 10331089
[PubMed]
Ambudkar SV et al: "Biochemical, cellular, and pharmacological aspects of the multidrug transporter."
No.
Sentence
Comment
47
Table 1 List of mutations in human, mouse, and hamster P-glycoproteins that affect substrate specificitya aa mutation Region Sourceb Reference H61R, F, K, M, W, Y TM 1 Human MDR1 149, 150 ABC20c G64R TM 1 Human MDR1 150 L65R TM 1 Human MDR1 150 aa78-97 EC 1 Human MDR1 151 Q128Hd TM 2 Mouse mdr3 152 R138H IC 1 Mouse mdr3 152 Q139H, R IC 1 Mouse mdr3 152 Q141V IC 1 Human MDR1 15319, Q145H IC 1 Mouse mdr3 152 E155G, K IC 1 Mouse mdr3 152 F159I IC 1 Mouse mdr3 152 D174G IC 1 Mouse mdr3 152 S176G, P IC 1 Mouse mdr3 152 K177I IC 1 Mouse mdr3 152 N179S IC 1 Mouse mdr3 152 N183S/G185V IC 1 Human MDR1 154 G183D IC 1 Mouse mdr3 152 G185V IC 1 Human MDR1 155-157 G187V IC 1 Human MDR1 153 A192T TM 3 Mouse mdr3 152 F204S EC 2 Mouse mdr3 152 W208G EC 2 Mouse mdr3 152 K209E EC 2 Mouse mdr3 152 L210I TM 4 Mouse mdr3 152 T211P TM 4 Mouse mdr3 152 I214T TM 4 Mouse mdr3 152 P223A TM 4 Human MDR1 158 G288V IC 2 Human MDR1 153 I299M, T319S, L322I, TM 5, EC3, Human MDR1 159 G324K, S351N IC 3 F335A TM 6 Human MDR1 19 F335 TM 6 Human MDR1 160 V338A TM 6 Human MDR1 161 G338A, A339P TM 6 Hamster PGY1 162, 163 A339P TM 6 Hamster PGY1 163 G341V TM 6 Human MDR1 161 K536R, Q N-NBD Human MDR1 164 ERGA → DKGT N-NBD Mouse mdr3 165 aa 522-525 T578C N-NBD Mouse mdr3 165 (Continued) G830V IC 4 Human MDR1 P866A TM 10 Human MDR1 158 F934A TM 11 Mouse mdr3 166 G935A TM 11 Mouse mdr3 166 I936A TM 11 Mouse mdr3 166 F938A TM 11 Mouse mdr3 166 S939A TM 11 Mouse mdr3 166 S939F TM 11 Mouse mdr3 167, 168 S941F TM 11 Mouse mdr1 167, 168 T941A TM 11 Mouse mdr3 166 Q942A TM 11 Mouse mdr3 166 A943G TM 11 Mouse mdr3 166 Y946A TM 11 Mouse mdr3 166 S948A TM 11 Mouse mdr3 166 Y949A TM 11 Mouse mdr3 166 C952A TM 11 Mouse mdr3 166 F953A TM 11 Mouse mdr3 166 F983A TM 12 Human MDR1 169 L975A, V981A, F983A TM 12 Human MDR1 169 M986A, V988A, Q990A, TM 12 Human MDR1 169 V991A V981A, F983A TM 12 Human MDR1 169 L975A, F983A TM 12 Human MDR1 169 L975A, V981A TM 12 Human MDR1 169 F978A TM 12 Human MDR1 19 a aa,amino acid; EC, extracellular loop; IC, intracellular loop; TM,transmembrane domain; NBD, nucleotide binding/utilization domain.
X
ABCB1 p.Phe983Ala 10331089:47:1741
status: NEWX
ABCB1 p.Phe983Ala 10331089:47:1782
status: NEWX
ABCB1 p.Phe983Ala 10331089:47:1864
status: NEWX
ABCB1 p.Phe983Ala 10331089:47:1898
status: NEW
PMID: 10350482
[PubMed]
Dey S et al: "A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol."
No.
Sentence
Comment
37
In this study we demonstrate that substitution of a single phenylalanine residue with alanine at position 983 in TM 12 of Pgp affects inhibition of Pgp-mediated drug transport by both cis(Z)- and trans(E)-flupentixol, and significantly alters their stereospecific effect on ATP hydrolysis and substrate recognition by Pgp, suggesting a common site of functional interaction for both isomers of flupentixol.
X
ABCB1 p.Phe983Ala 10350482:37:59
status: NEW126 RESULTS Substitution of Phenylalanine Residue 983 with Alanine SelectiVely Affects Inhibition of Drug Transport by both cis(Z)- and trans(E)-Flupentixol.
X
ABCB1 p.Phe983Ala 10350482:126:24
status: NEW127 In a recent study, seven amino acid residues, L975, V981, F983, M986, V988, Q990, and V991, in the putative TM 12 of human Pgp were substituted individually by alanine (L975A, V981A, F983A, M986A, V988A, Q990A, and V991A).
X
ABCB1 p.Phe983Ala 10350482:127:183
status: NEW133 Consistent with the previous report, all the mutant Pgp`s (L975A, V981A, F983A, M986A, V988A, Q990A, and V991A) were expressed on the cell surface at a comparable level to that of wild-type (WT) Pgp (Figure 1A, upper panel).
X
ABCB1 p.Phe983Ala 10350482:133:73
status: NEW141 Human osteosarcoma (HOS) cells infected with vTF7-3 were transfected with either pTM1 (control) (s), pTM1-MDR1 (wild type) (-), pTM1-MDR1-L975A (L975A) (‚‚‚), pTM1-MDR1-V981A (V981A) (- - -), pTM1-MDR1-F983A (F983A) (- -), pTM1-MDR1-M986A (M986A) (thick dashes), pTM1-MDR1-V988A (V988A) (-‚‚-), pTM1-MDR1-Q990A (Q990A) (-‚-), or pTM1-MDR1-V991A (V991A) (-‚‚‚-) plasmid DNA.
X
ABCB1 p.Phe983Ala 10350482:141:223
status: NEWX
ABCB1 p.Phe983Ala 10350482:141:230
status: NEW143 (A, upper panel) Cells were subjected to FACS analysis after staining with human Pgp external epitope-specific monoclonal antibody MRK-16 (14), as described under Experimental Procedures. (A, lower panel) Total cell lysates were prepared from each cell type, and immunoblot analysis with Pgp-specific monoclonal antibody C219 was performed as described under Experimental Procedures. (B) Similar to section A; cells were infected with vTF7-3, and transfected with either pTM1 (control) (s), pTM1-MDR1 (wild type) (-), pTM1-MDR1-L975A (L975A) (‚‚‚), pTM1-MDR1-V981A (V981A) (- - -), pTM1-MDR1-F983A (F983A) (- -), pTM1-MDR1-M986A (M986A) (thick dashes) pTM1-MDR1-V988A (V988A) (-‚‚-), pTM1-MDR1-Q990A (Q990A) (-‚-), or pTM1-MDR1-V991A (V991A) (-‚‚‚-) plasmid DNAs.
X
ABCB1 p.Phe983Ala 10350482:143:613
status: NEWX
ABCB1 p.Phe983Ala 10350482:143:620
status: NEW157 However, the steady-state accumulation of the verapamil derivative in cells expressing F983A was minimally altered in the presence of 10 µM cis(Z)- or 5 µM trans(E)-flupentixol (Figure 2A,B), suggesting an impaired ability of this mutant to respond to inhibition of drug transport by both isomers of flupentixol.
X
ABCB1 p.Phe983Ala 10350482:157:87
status: NEW160 Since substitution of F983 had the most profound effect on the inhibitory potential of flupentixol, the mutant F983A was our obvious choice for further characterization.
X
ABCB1 p.Phe983Ala 10350482:160:111
status: NEW161 Stimulation of ATP Hydrolysis by cis(Z)-Flupentixol Is Considerably Altered in F983A.
X
ABCB1 p.Phe983Ala 10350482:161:79
status: NEW163 Since drug transport by F983A was considerably less sensitive to inhibition by cis(Z)- flupentixol, we studied the ability of cis(Z)-flupentixol to modulate the rate of ATP hydrolysis by this mutant.
X
ABCB1 p.Phe983Ala 10350482:163:24
status: NEW165 Steady-state accumulation of Bodipy FL-verapamil was measured by FACS in the presence (- - -) and absence (s) of 10 µM cis(Z)-flupentixol (A) or 5 µM trans(E)-flupentixol (B) in HOS cells infected with vTF7-3 and transfected with either pTM1 (pTM1), pTM1-MDR1 (WT), pTM1-MDR1-L975A (L975A), pTM1-MDR1-V981A (V981A), or pTM1-MDR1-F983A (F983A).
X
ABCB1 p.Phe983Ala 10350482:165:339
status: NEWX
ABCB1 p.Phe983Ala 10350482:165:346
status: NEW166 For details, see Experimental Procedures. the wild-type Pgp or F983A, and Pgp-ATPase activity was measured in the presence of varying concentrations of either verapamil or cis(Z)-flupentixol.
X
ABCB1 p.Phe983Ala 10350482:166:65
status: NEW167 Consistent with their ability to transport Bodipy FL-verapamil, ATP hydrolysis by both wild-type Pgp and F983A in isolated membranes was stimulated by verapamil in a concentration-dependent manner (Figure 3A).
X
ABCB1 p.Phe983Ala 10350482:167:105
status: NEW168 Although the rate of ATP hydrolysis by F983A in the absence of verapamil was about 70% of that of the wild-type Pgp, the verapamil-stimulated activity was about the same in both Pgp`s.
X
ABCB1 p.Phe983Ala 10350482:168:39
status: NEW169 A maximum rate of ATP hydrolysis between 25 and 28 nmol mg-1 min-1 was achieved by both wild-type and F983A at a verapamil concentration of 25 µM.
X
ABCB1 p.Phe983Ala 10350482:169:102
status: NEW173 In contrast, stimulation by cis(Z)-flupentixol of ATP hydrolysis by F983A was significantly impaired, with a maximum of only 12-14 nmol mg-1 min-1 of ATP hydrolyzed at cis(Z)- flupentixol concentrations of 50 µM (Figure 3B).
X
ABCB1 p.Phe983Ala 10350482:173:68
status: NEW174 Due to a low basal rate of ATP hydrolysis by F983A, the fold stimulation by cis(Z)-flupentixol (2-fold) was about the same for both wild-type Pgp and F983A; however, in F983A this was achieved at a considerably higher concentration (Figure 3B).
X
ABCB1 p.Phe983Ala 10350482:174:45
status: NEWX
ABCB1 p.Phe983Ala 10350482:174:150
status: NEWX
ABCB1 p.Phe983Ala 10350482:174:169
status: NEW175 The Ability of trans(E)-Flupentixol To Inhibit Verapamil-Stimulated ATP Hydrolysis Is Markedly Reduced in F983A.
X
ABCB1 p.Phe983Ala 10350482:175:106
status: NEW176 Since Bodipy FL-verapamil transport by F983A was less sensitive to inhibition by trans(E)-flupentixol, we studied its effect on verapamil-stimulated ATP hydrolysis by F983A. Isolated cell membranes from HeLa cells, expressing either wild-type Pgp or F983A, were preincubated with varying concentrations of trans(E)-flupentixol prior to the measurement of vanadate-sensitive ATP hydrolysis in the presence of 25 µM verapamil.
X
ABCB1 p.Phe983Ala 10350482:176:39
status: NEWX
ABCB1 p.Phe983Ala 10350482:176:167
status: NEWX
ABCB1 p.Phe983Ala 10350482:176:250
status: NEW177 Consistent with the previous experiment, in the absence of trans(E)-flupentixol the rate of verapamil-stimulated ATP hydrolysis by the wild-type and the mutant (F983A) was around 26 nmol mg-1 min-1.
X
ABCB1 p.Phe983Ala 10350482:177:161
status: NEW179 In contrast, the ability of trans(E)- flupentixol to inhibit verapamil-stimulated ATP hydrolysis by F983A was significantly reduced (Figure 4A).
X
ABCB1 p.Phe983Ala 10350482:179:100
status: NEW181 This indicated that residue F983A also plays a crucial role in the inhibition of ATP hydrolysis by trans(E)-flupentixol.
X
ABCB1 p.Phe983Ala 10350482:181:28
status: NEW182 To determine whether the loss of sensitivity to trans(E)- flupentixol in F983A reflected a general defect of the mutant FIGURE 3: Effect of verapamil and cis(Z)-flupentixol on ATP hydrolysis by the wild-type and F983A Pgp`s.
X
ABCB1 p.Phe983Ala 10350482:182:73
status: NEWX
ABCB1 p.Phe983Ala 10350482:182:212
status: NEW183 Membranes were isolated from HeLa cells infected with vTF7-3 and transfected with either pTM1, pTM1-MDR1 (WT), or pTM1-MDR1-F983A (F983A) plasmid DNAs.
X
ABCB1 p.Phe983Ala 10350482:183:124
status: NEWX
ABCB1 p.Phe983Ala 10350482:183:131
status: NEW184 HeLa cell membranes (20 µg of protein) containing wild-type Pgp (0) or F983A (b) were incubated either with the indicated concentrations of verapamil (A) or with cis(Z)-flupentixol (B) prior to measuring the rate of ATP hydrolysis.
X
ABCB1 p.Phe983Ala 10350482:184:76
status: NEW188 FIGURE 4: Effect of trans(E)-flupentixol and cyclosporin A on verapamil-stimulated ATP hydrolysis by the wild-type and F983A Pgp`s.
X
ABCB1 p.Phe983Ala 10350482:188:119
status: NEW189 Vanadate-sensitive ATP hydrolysis by wild-type Pgp (0) and F983A (b) (20 µg of membrane protein) in HeLa cell membranes was measured as described in Figure 3, in the presence of 5 mM ATP, 10 mM MgCl2, 25 µM verapamil, and the indicated concentrations of either trans(E)-flupentixol (A) or cyclosporin A (B).
X
ABCB1 p.Phe983Ala 10350482:189:59
status: NEW192 in its ability to respond to inhibitors of Pgp-ATPase activity, we studied the effect of cyclosporin A on verapamil-stimulated ATP hydrolysis by wild-type Pgp and F983A.
X
ABCB1 p.Phe983Ala 10350482:192:163
status: NEW193 Cyclosporin A inhibited verapamil-stimulated ATPase activity with equal potency in both wild type and F983A (Figure 4B).
X
ABCB1 p.Phe983Ala 10350482:193:102
status: NEW194 The concentrations for half-maximal inhibition were about 0.4 µM for both wild type and F983A.
X
ABCB1 p.Phe983Ala 10350482:194:93
status: NEW196 Stimulation by cis(Z)-Flupentixol of Photoaffinity Labeling with the Substrate Analogue [125 I]IAAP Is Considerably Affected in F983A.
X
ABCB1 p.Phe983Ala 10350482:196:128
status: NEW198 Since cis(Z)-flupentixol was unable to reverse drug transport by F983A, we examined the effect of cis(Z)-flupentixol on [125 I]IAAP labeling of F983A. Isolated membranes from HeLa cells expressing wild-type Pgp or F983A were photoaffinity labeled with 4 nM [125 I]IAAP in the presence of varying (0-100 µM) concentrations of cis(Z)-flupentixol.
X
ABCB1 p.Phe983Ala 10350482:198:65
status: NEWX
ABCB1 p.Phe983Ala 10350482:198:144
status: NEWX
ABCB1 p.Phe983Ala 10350482:198:214
status: NEW200 In contrast, stimulation of [125I]IAAP labeling was significantly reduced in F983A (Figure 5B) with a maximal stimulation of only 2-fold (Figure 5C).
X
ABCB1 p.Phe983Ala 10350482:200:77
status: NEW201 However, stimulation reached its maximum at the same concentration of cis(Z)- flupentixol (10 µM) for both wild-type Pgp and F983A (Figure 5C).
X
ABCB1 p.Phe983Ala 10350482:201:130
status: NEW205 Photoaffinity Labeling of F983A with [125I]IAAP Is RelatiVely Resistant to Inhibition by trans(E)-Flupentixol.
X
ABCB1 p.Phe983Ala 10350482:205:26
status: NEW209 Inhibition of [125I]IAAP labeling by trans(E)-flupentixol was considerably altered in F983A, in which case the concentration of trans(E)-flupentixol required for half-maximal inhibition was about 4-fold higher (about 40 µM) than that for the wild-type Pgp.
X
ABCB1 p.Phe983Ala 10350482:209:86
status: NEW210 Photoaffinity labeling of the wild-type Pgp and F983A with [125 I]IAAP was also carried out in the presence of varying concentrations of cyclosporin A.
X
ABCB1 p.Phe983Ala 10350482:210:48
status: NEW212 Concentrations of cyclosporin A required for half-maximal and maximal inhibitions were around 0.035 µM for both wild-type Pgp and F983A.
X
ABCB1 p.Phe983Ala 10350482:212:135
status: NEW213 This excluded the possibility of a general loss of sensitivity to inhibitors of substrate recognition in F983A.
X
ABCB1 p.Phe983Ala 10350482:213:105
status: NEW218 In this study we demonstrate that a single substitution of alanine for phenylalanine at position 983 in the putative TM 12 of Pgp markedly alters the ability of both cis and trans isomers of flupentixol to modulate ATPase activity and [125 I]IAAP labeling of Pgp, and also FIGURE 5: Effect of cis(Z)-flupentixol on [125I]IAAP labeling of the wild-type Pgp and F983A.
X
ABCB1 p.Phe983Ala 10350482:218:59
status: NEWX
ABCB1 p.Phe983Ala 10350482:218:360
status: NEW219 Membranes were isolated from HeLa cells infected with vTF7-3 and transfected with either (A) pTM1-MDR1 (WT) or (B) pTM1-MDR1-F983A (F983A) plasmid DNAs.
X
ABCB1 p.Phe983Ala 10350482:219:125
status: NEWX
ABCB1 p.Phe983Ala 10350482:219:132
status: NEW221 (C) Quantification of radioactivity associated with the wild-type (0) and F983A (b) Pgp`s bands was done by a STORM 860 phosphorimaging system as described under Experimental Procedures.
X
ABCB1 p.Phe983Ala 10350482:221:74
status: NEW239 Although drug transport was inhibited by both cis(Z)- and trans(E)-flupentixol in V981A and M986A (data not shown), inhibition was not complete, FIGURE 6: Effect of trans(E)-flupentixol and cyclosporin A on [125I]IAAP labeling of the wild-type Pgp and F983A.
X
ABCB1 p.Phe983Ala 10350482:239:252
status: NEW240 HeLa membranes (25 µg of protein) containing either wild-type Pgp (top) or F983A (bottom) were preincubated at room temperature in the presence of the indicated concentrations of either trans(E)-flupentixol (A) or cyclosporin A (B) prior to incubation with 4 nM [125I]IAAP, for 10 min, as described under Experimental Procedures. Following incubation, membranes were photo-cross-linked, and 10 µg of membrane proteins was analyzed by SDS-PAGE and subjected to autoradiography.
X
ABCB1 p.Phe983Ala 10350482:240:80
status: NEW243 Radioactivity associated with the wild-type (0) and F983A (b) Pgp bands was expressed as percent control using the same method as in Figure 5.
X
ABCB1 p.Phe983Ala 10350482:243:52
status: NEW246 It is to be noted that in all three mutants (F983A, V981A, and M986A) the inhibitory effect of both isomers (cis and trans) of flupentixol was affected.
X
ABCB1 p.Phe983Ala 10350482:246:45
status: NEW255 In F983A the inhibitory effect of cis(Z)- and trans(E)-flupentixol on Pgp-mediated drug transport was considerably reduced without much alteration in the ability of the protein to transport substrates (Figures 1B and 2A,B).
X
ABCB1 p.Phe983Ala 10350482:255:3
status: NEW257 Therefore, this dissociation of susceptibility to inhibition by flupentixol from drug transport in F983A strongly indicates the allosteric nature of the flupentixol interaction site with Pgp.
X
ABCB1 p.Phe983Ala 10350482:257:99
status: NEW258 Consistent with this, in F983A the modulatory potency of cis(Z)- and trans(E)-flupentixol on ATP hydrolysis and [125I]IAAP labeling were significantly altered with only a minimal effect on the basal level of ATPase activity and [125 I]IAAP labeling.
X
ABCB1 p.Phe983Ala 10350482:258:25
status: NEW266 Consistent with the idea of a single site of interaction, both cis(Z)-flupentixol-mediated stimulation (Figure 5C) and trans(E)-flupentixol-mediated inhibition (Figure 6A) of [125I]IAAP labeling were also significantly reduced in F983A.
X
ABCB1 p.Phe983Ala 10350482:266:230
status: NEW269 In F983A, stimulation of [125I]IAAP labeling was significantly altered with a maximal stimulation of only 2-fold compared to 9-fold stimulation in the wild-type Pgp (Figure 5A-C).
X
ABCB1 p.Phe983Ala 10350482:269:3
status: NEW270 However, the decrease in stimulation of [125I]IAAP labeling was evident at the same concentration of cis(Z)-flupentixol for both F983A and wild-type Pgp.
X
ABCB1 p.Phe983Ala 10350482:270:129
status: NEW
PMID: 10724034
[PubMed]
Hafkemeyer P et al: "Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug-resistant cancers."
No.
Sentence
Comment
3
We report here that retroviral vectors encoding a mutant P-glycoprotein (MDR1-F983A) protect hematopoietic cells from anticancer drugs even in the presence of trans-(E)-flupentixol, an inhibitor of P-glycoprotein.
X
ABCB1 p.Phe983Ala 10724034:3:78
status: NEW42 We have introduced a point mutation that leads to a substitution of phenylalanine by alanine in position 983.
X
ABCB1 p.Phe983Ala 10724034:42:68
status: NEW45 In the present work, we have constructed retroviral vectors containing this mutant MDR1-F983A cDNA.
X
ABCB1 p.Phe983Ala 10724034:45:88
status: NEW46 With the exception of the inserted point mutation, pHaMA-F983A is identical to a previously described vector, pHaMA (Pastan et al., 1988; Metz et al., 1995), with long-term inal repeats (LTRs) from Harvey sarcoma virus.
X
ABCB1 p.Phe983Ala 10724034:46:57
status: NEW48 The MDR1-F983A vectors were characterized in KB-3-1 epidermoid cancer cells, and hematopoietic cells from the K562 erythroleukemia line or primary mouse bone marrow.
X
ABCB1 p.Phe983Ala 10724034:48:9
status: NEW51 To construct vector pHaMA-F983A, the NsiI-XhoI fragment of previously described plasmid pTM1MDR1 (Hafkemeyer et al., 1998) containing the F983A-mutant fragment was cloned into the corresponding sites of pHaMA.
X
ABCB1 p.Phe983Ala 10724034:51:26
status: NEWX
ABCB1 p.Phe983Ala 10724034:51:138
status: NEW53 The vectors LZRS- pBMN-MDR1 and LZRS-pBMN-MDR1-F983A, respectively, were obtained after excision of lacZ by EcoRI digest of LZRS- pBMN-lacZ, and blunt ending of the vector backbone with T4 polymerase and Klenow enzyme.
X
ABCB1 p.Phe983Ala 10724034:53:47
status: NEW54 pHaMA and pHaMA-F983A were then blunt ended after SacII-XhoI digestion.
X
ABCB1 p.Phe983Ala 10724034:54:16
status: NEW55 The thereby obtained MDR1 and MDR1-F983A fragments, respectively, were ligated into the EcoRI-digested and blunt-ended backbone of LZRS-pBMN-lacZ to yield LZRS-pBMN-MDR1 and LZRS- pBMN-MDR1-F983A.
X
ABCB1 p.Phe983Ala 10724034:55:35
status: NEWX
ABCB1 p.Phe983Ala 10724034:55:190
status: NEW61 Cell transfections and transductions KB-3-1 cells were transfected by calcium phosphate coprecipitation with 10 m g of plasmid DNA (pHaMA or pHaMA-F983A) per 1 3 105 cells as described (Germann et al., 1989).
X
ABCB1 p.Phe983Ala 10724034:61:147
status: NEW64 The same method was used to generate ecotropic retroviral producer cells from GP1 E86 packaging cells (ATCC) with plasmid pHaMA-F983A.
X
ABCB1 p.Phe983Ala 10724034:64:128
status: NEW67 Wild-type and F983A-mutant MDR1 producer lines were obtained by transient transfection with 10 m g of either LZRS- pBMN-MDR1 or LZRS-pBMN-MDR1-F983A, respectively.
X
ABCB1 p.Phe983Ala 10724034:67:14
status: NEWX
ABCB1 p.Phe983Ala 10724034:67:143
status: NEW81 To assess the chemosensitivity of K562 parental cells, and of K562 cells transduced with either the LZRS-pBMN-MDR1 or LZRS- pBMN-MDR1-F983A construct, 200 cells/ml were mixed with daunomycin (Calbiochem , San Diego, CA) and trans-(E)-flupentixol (RBI, Natick, MA) at various concentrations in MethoCult 4330 medium containing 0.8% methylcellulose (Stem Cell Technologies, Vancouver, BC, Canada).
X
ABCB1 p.Phe983Ala 10724034:81:134
status: NEW85 RESULTS Reversal of the functional activity of wild-type P-gp in KB cancer cells We first analyzed the reversing potential of trans-(E)-flupentixol in multidrug-resist ant cells expressing either the wild-type or the F983A-mutant P-gp.
X
ABCB1 p.Phe983Ala 10724034:85:217
status: NEW90 We also analyzed KB-3-1 cells stably transfected with MDR1-containing plasmids, pHaMA or pHaMA-F983A, and selected with vincristine; clones G2 (wild-type) and 7A (mutant) expressed similar levels of P-gp (Fig. 1a).
X
ABCB1 p.Phe983Ala 10724034:90:95
status: NEW97 At 2 m M trans-(E)-flupentixol, 7A cells expressing F983A-mutant P-gp accumulated three- to fivefold less [3H]daunomycin than G2 cells (Fig. 1b).
X
ABCB1 p.Phe983Ala 10724034:97:52
status: NEW104 (a)DetectionofP-gponthecellsurfaceofparentalKB-3-1cellsandmul- tidrug-resistantKB-8-5cells,andKB-3-1cellsstablytransfectedwithpHaMA(wild-typeMDR1,cloneG2)orpHaMA-F983A(mutantMDR1-F983A,clone7A).Cellswerestained with5mgofmonoclonalantibodyMRK16(specificforhumanP-gp)conjugatedtoFITC,oranequalconcentrationofanisotype-identifiedcontrolantibody.Afterwashing,cells wereanalyzedbyflowcytometry.
X
ABCB1 p.Phe983Ala 10724034:104:179
status: NEW106 A, another P-gp inhibitor, was comparable in all investigated KB cells, regardless of the presence of the F983A point mutation (data not shown).
X
ABCB1 p.Phe983Ala 10724034:106:106
status: NEW107 Development of retroviruses containing mutant MDR1-F983A for transduction of hematopoietic cells Ecotropic retroviral producer cells were generated by stable transfection of GP1 E86 packaging cells with plasmid pHaMA-F983A (Fig. 4a).
X
ABCB1 p.Phe983Ala 10724034:107:51
status: NEWX
ABCB1 p.Phe983Ala 10724034:107:217
status: NEW112 Transduction levels for the EBV-retroviral vectors containing mutant or wild-type MDR1 cDNAs were 80% (LZRS-pBMN-MDR1-F983A) and 68% (LZRS-pBMN-MDR1) over background.
X
ABCB1 p.Phe983Ala 10724034:112:118
status: NEW114 EBV-hybrid vectors with titers of 5-7 3 105 CFU/ml were generated by transient transfection of amphotropic 293T (Phoenix) cells with plasmid LZRS-pBMN-MDR1 (wild-type) or LZRS-pBMN-MDR1-F983A (mutant).
X
ABCB1 p.Phe983Ala 10724034:114:186
status: NEW118 Modulation of drug transport by trans-(E)-flupentixol in hematopoietic cells transduced with F983A-mutant or wild-type MDR1 vectors Transfer of either the F983A-mutant or the wild-type MDR1 cDNA to K562 cells caused them to accumulate far less [3H]daunomycin and [3H]vinblastine than the non-MDR1 control (Fig. 5b).
X
ABCB1 p.Phe983Ala 10724034:118:93
status: NEWX
ABCB1 p.Phe983Ala 10724034:118:155
status: NEW123 Parental K562 cells formed only a few colonies in the presence of daunomycin (10 ng/ml) but transfer of the wild-type or the F983A-mutant MDR1 cDNA rendered them resistant to this concentration.
X
ABCB1 p.Phe983Ala 10724034:123:125
status: NEW129 retroviruses containing F983A-mutant MDR1 but reduced the number of resistant colonies from cells expressing wild-type P-gp.
X
ABCB1 p.Phe983Ala 10724034:129:24
status: NEW130 Moreover, daunomycin at 30 ng/ml, combined with 2 m M trans-(E)-flupentixol, killed all cells transduced with wild-type MDR1 while 10% of the respective cells transduced with the F983A-mutant vector were protected.
X
ABCB1 p.Phe983Ala 10724034:130:179
status: NEW131 Thus, K562 cells expressing wild-type MDR1 were slightly more chemoresistant than those transduced with the mutant vector, but this resistance was not reversible in cells expressing F983A-MDR1.
X
ABCB1 p.Phe983Ala 10724034:131:182
status: NEW138 Drug extrusion from K562 cells transduced with the mutant MDR1-F983A vector was not overcome by trans-(E)-flupentixol at concentrations that reverse P-gp function in KB-8-5 cells.
X
ABCB1 p.Phe983Ala 10724034:138:63
status: NEW139 Correspondingly , daunomycin resistance was reversible only in K562 cells that had been transduced with wild-type but not with the F983A-mutant MDR1 cDNA.
X
ABCB1 p.Phe983Ala 10724034:139:131
status: NEW141 Although P-gp expression levels and the total amount of drug efflux were lower than in the K562 cell population because no selection was applied, trans-(E)-flupentixol failed to reverse drug efflux from BMCs transduced with the mutant MDR1-F983A vector.
X
ABCB1 p.Phe983Ala 10724034:141:240
status: NEW153 (a)MapsoftheproviralstructuresofpHaMAandpHaMA-F983Acon- tainingfull-lengthwild-typeormutantMDR1cDNAs,respectively.TheEBV-derivedretroviralhybridvectorsareLZRS-pBMN-MDR1,containingawild-typeMDR1cDNA,and LZRS-pBMN-MDR1-F983A,containingtherespectivemutantMDR1-F983AcDNA.
X
ABCB1 p.Phe983Ala 10724034:153:217
status: NEW155 (c)ExpressionofP-gpinK562cellstransduced witheitherLZRS-pBMN-MDR1-F983A,LZRS-pBMN-MDR1,orLZRS-pBMN-lacZ(negativecontrol).Aftercoculturewithretroviralproducersfor48hr,transducedK562cells wereselectedwithvincristine(100ng/ml)for18days.Cellswerestainedwith5mgofantibodyMRK16conjugatedtoFITCoranFITC-labeledcontrolantibody.After30min, cellswerewashed,andfluorescenceintensitieswereanalyzedbyflowcytometry.Nonviablecellswereexcludedbypropidiumiodidecounterstaining.
X
ABCB1 p.Phe983Ala 10724034:155:66
status: NEW162 The advantage of amphotropic, EBV-based hybrid vectors, LZRS-pBMN-MDR1 and LZRS-pBMN-MDR1-F983A, is rapid production of retroviruses after transient transfection (Nolan and Shatzman, 1998).
X
ABCB1 p.Phe983Ala 10724034:162:90
status: NEW169 (a) Murine BMCs were transduced in cocultures with vectors GP1 E86 MDR1-F983A (d ), GP1 E86 MDR1/A (wild-type) (r ), or packaging cells (h ) that did not confer drug resistance.
X
ABCB1 p.Phe983Ala 10724034:169:72
status: NEW171 (b) K562 cells, transduced and selected as described in the legend to Fig. 4c, were analyzed under identical conditions (h , negative control; r , LZRS-pBMN-MDR1; d , LZRS-pBMN-MDR1-F983A).
X
ABCB1 p.Phe983Ala 10724034:171:182
status: NEW183 High concentrations of trans-(E)-flupentixol (20 m M and higher) are not useful because they reduce chemoprotection of hematopoietic cells mediated by the F983A-MDR1 transgene (Fig. 5).
X
ABCB1 p.Phe983Ala 10724034:183:155
status: NEW185 The mutation F983A in the putative transmembrane domain TM 12 had little effect on drug binding to P-gp but almost abolished cis-(Z)-flupentixol-stim ulated ATPase activity of the transporter (Dey et al., 1999).
X
ABCB1 p.Phe983Ala 10724034:185:13
status: NEW
PMID: 12172212
[PubMed]
Tang K et al: "Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations."
No.
Sentence
Comment
18
It has been reported that cells carrying the F983A change exhibit increased resistance to reversal by flupentixol but not other drugs [6], while cells carrying the G185V change have increased resistance to colchicine but not other drugs [7,8].
X
ABCB1 p.Phe983Ala 12172212:18:45
status: NEW
PMID: 12642584
[PubMed]
Maki N et al: "Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation."
No.
Sentence
Comment
6
A single amino acid substitution (F983A) in TM12 of Pgp that impairs inhibition by cis-(Z)-flupentixol of Pgp-mediated drug transport also affects stabilization of the Pgp-substrate complex as well as the characteristic conformational change.
X
ABCB1 p.Phe983Ala 12642584:6:34
status: NEW45 In addition, two cell lines NIHMDR1-WT and NIHMDR1-F983A were generated.
X
ABCB1 p.Phe983Ala 12642584:45:51
status: NEW46 NIHMDR1-WT and NIHMDR1-F983A were created by stepwise selection of NIH3T3 cells transfected with pHaMDR1 and pHaMDR1-F983A plasmids, respectively.
X
ABCB1 p.Phe983Ala 12642584:46:23
status: NEWX
ABCB1 p.Phe983Ala 12642584:46:117
status: NEW48 To construct the vector pHaMDR1-F983A, the NsiI-XhoI fragment of the previously described plasmid pTM1MDR1 containing the F983A mutation (25) was cloned into the corresponding sites of pHaMDR1.
X
ABCB1 p.Phe983Ala 12642584:48:32
status: NEWX
ABCB1 p.Phe983Ala 12642584:48:122
status: NEW49 The region corresponding to the NdeI-PstI fragment within pHaMDR1-F983A including the insertion points and the flanking regions was sequenced in its entirety in both directions by automated sequencing (PRISM Ready Reaction DyeDeoxy Terminator Sequencing Kit, PerkinElmer Life Sciences).
X
ABCB1 p.Phe983Ala 12642584:49:66
status: NEW50 The plasmids pHaMDR1 and pHaMDR1-F983A were calcium phosphate-transfected into NIH3T3 cells and selected with vincristine.
X
ABCB1 p.Phe983Ala 12642584:50:33
status: NEW52 A stepwise selection was carried out with increasing concentrations of vincristine to generate NIHMDR1-WT and NIHMDR1-F983A cell lines that were able to grow in the presence of 1 M vincristine.
X
ABCB1 p.Phe983Ala 12642584:52:118
status: NEW164 A Single Amino Acid Substitution That Alters the Inhibitory Potential of cis-(Z)-Flupentixol Also Affects cis-(Z)-Flupentixol-induced Formation of Pgp-[125 I]IAAP Complex-To determine the functional significance of the Pgp-[125 I]IAAP complex formation and the elevated level of [125 I]IAAP associated with Pgp-expressing cells in the presence of cis-(Z)-flupentixol, both phenomena were tested in the Pgp mutant F983A, which is largely insensitive to modulation by cis-(Z)-flupentixol (22).
X
ABCB1 p.Phe983Ala 12642584:164:413
status: NEW165 The intracellular accumulation of [125 I]IAAP in cells expressing either the wild-type Pgp (NIHMDR1-WT) or the mutant F983A Pgp (NIHMDR1-F983A) was considerably lower than that of the control NIH3T3 cells, suggesting efficient transport of [125 I]IAAP by both the wild-type and F983A mutant Pgp.
X
ABCB1 p.Phe983Ala 12642584:165:118
status: NEWX
ABCB1 p.Phe983Ala 12642584:165:137
status: NEWX
ABCB1 p.Phe983Ala 12642584:165:278
status: NEW166 However, the elevated level of cellular [125 I]IAAP association, in the presence of 5 M cis-(Z)-flupentixol, was selectively abrogated in NIHMDR1-F983A (Fig. 4A).
X
ABCB1 p.Phe983Ala 12642584:166:154
status: NEW167 Photocross-linking for 5 min at the end of the uptake assay showed no increase in interaction (photocross-linking) between [125 I]IAAP and F983A by cis-(Z)-flupentixol, although under the same conditions increased complex formation was observed between wild-type Pgp and [125 I]IAAP in NIHMDR1-WT cells (Fig. 4B, upper panel).
X
ABCB1 p.Phe983Ala 12642584:167:139
status: NEW168 In the absence of cis-(Z)-flupentixol, there was no significant difference in the interaction with [125 I]IAAP between the wild-type and the F983A mutant.
X
ABCB1 p.Phe983Ala 12642584:168:141
status: NEW169 Cyclosporin A (5 M), a competitive inhibitor of Pgp, inhibited both transport and [125 I]IAAP binding by wild-type and F983A with similar efficiency (Fig. 4B, upper panel).
X
ABCB1 p.Phe983Ala 12642584:169:127
status: NEW170 Similar results were obtained from experiments with membranes isolated from NIHMDR1-WT and NIHMDR1-F983A cells (Fig. 4B, lower panel).
X
ABCB1 p.Phe983Ala 12642584:170:99
status: NEW176 To investigate the mechanistic significance of this conformational change, UIC2 reactivity was studied in cells expressing the Pgp mutant F983A, which has impaired sensitivity to inhibition by cis-(Z)- flupentixol (Fig. 5B).
X
ABCB1 p.Phe983Ala 12642584:176:138
status: NEW177 cis-(Z)-Flupentixol was unable to induce any negative effect on UIC2 binding to NIHMDR1-F983A cells FIG. 3.
X
ABCB1 p.Phe983Ala 12642584:177:88
status: NEW190 Because increased or decreased UIC2 reactivity induced by cyclosporin A or vanadate, respectively, was unaffected in NIHMDR1-F983A (Fig. 5B), compared with that observed in NIHMDR1-WT cells, the possibility of a nonspecific effect could be ruled out.
X
ABCB1 p.Phe983Ala 12642584:190:125
status: NEW204 NIH3T3, NIHMDR1-WT (wild-type Pgp), and NIHMDR1-F983A (mutant F983A) cells were incubated with 1.5 nM [125 I]IAAP in the presence and absence of 5 M cis-(Z)-flupentixol for 60 min at 37 °C.
X
ABCB1 p.Phe983Ala 12642584:204:48
status: NEWX
ABCB1 p.Phe983Ala 12642584:204:62
status: NEW207 Data points represent average value of three identical experiments. B, interaction of [125 I]IAAP with wild-type (WT) Pgp and F983A, in intact cells (upper panel) and in isolated membranes (lower panel).
X
ABCB1 p.Phe983Ala 12642584:207:126
status: NEW218 B, UIC2 reactivity of Pgp mutant F983A.
X
ABCB1 p.Phe983Ala 12642584:218:33
status: NEW219 UIC2 binding to NIHMDR1-WT and NIHMDR1-F983A cells was carried out as mentioned above either in the presence of 1 mM sodium orthovanadate (Vi), 5 M cis-(Z)-flupentixol (Cis(Z)), 5 M cyclosporin A (CsA), or in the absence of any modulators.
X
ABCB1 p.Phe983Ala 12642584:219:39
status: NEW260 Interestingly, formation of the stable Pgp-[125 I]IAAP complex induced by cis-(Z)-flupentixol was remarkably affected in the Pgp mutant F983A (Fig. 4B), drug transport function by which is not inhibited by cis-(Z)-flupentixol (Fig. 4A).
X
ABCB1 p.Phe983Ala 12642584:260:136
status: NEW262 Because the mutation F983A did not affect [125 I]IAAP transport or the ability of cyclosporin A to block the substrate site (Fig. 4B) and inhibit transport (Fig. 4A), any global effect of the mutation can be ruled out.
X
ABCB1 p.Phe983Ala 12642584:262:21
status: NEW270 No such conformational change was induced by cis-(Z)- flupentixol in the Pgp mutant F983A, whereas the ability of the competitive inhibitor cyclosporin A to induce its characteristic change in conformation remained unaltered (Fig. 5B), underscoring the functional distinctness of the allosteric site.
X
ABCB1 p.Phe983Ala 12642584:270:84
status: NEW
No.
Sentence
Comment
87
Cell lines expressing wt and mutant proteins were subjected to accumulation studies using Bodipy FL-verapamil in the presence of cis(Z)- or trans(E)- flupentixol. Both flupentixol isomers were shown to loose their inhibitory function in the F983A mutant.
X
ABCB1 p.Phe983Ala 15720286:87:241
status: NEW88 The large increase in labeling with [125I]IAAP in the presence of cis(Z)-flupentixol was lost in the F983A mutant.
X
ABCB1 p.Phe983Ala 15720286:88:101
status: NEW90 A general loss of sensitivity to inhibitors was excluded, because labeling of F983A with IAAP stayed sensitive to Cyclosporin A inhibition.
X
ABCB1 p.Phe983Ala 15720286:90:78
status: NEW
PMID: 16178819
[PubMed]
Breier A et al: "P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy."
No.
Sentence
Comment
185
Several other authors described modulation of drug efflux capacity of mutant P-gp after site directed mutagenesis of an amino acid in the transmembrane domains, e.g. histidine 61 in domain 1 [134], single serines replacements by phenylalanines in transmembrane domain 11 [135], leucine 975, valine 981 and phenylalanine 983 by alanine in transmembrane domain 12 [136].
X
ABCB1 p.Phe983Ala 16178819:185:306
status: NEW
PMID: 16489767
[PubMed]
Maki N et al: "Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein."
No.
Sentence
Comment
7
In the Pgp F983A mutant, which is impaired in modulation by cis-(Z)-flupentixol, the modulator has a minimal effect on substrate-stimulated ATP hydrolysis as well as on substrate dissociation coupled to vanadate trapping.
X
ABCB1 p.Phe983Ala 16489767:7:11
status: NEW24 1 Abbreviations: Pgp, P-glycoprotein; [125 I]IAAP, [125 I]iodoarylazidoprazosin; [R-32 P]-8N3ATP, [R-32 P]-8-azido-ATP; ATP, adenosine triphosphate; ADP, adenosine diphosphate; TM, transmembrane; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; Cis(Z), cis-(Z)-flupentixol; CsA, cyclosporin A; Vi, vanadate; F983A, Pgp F983A mutant; EGTA, ethylene glycol bis( -aminoethyl)-N,N,N',N'- tetraacetic acid.
X
ABCB1 p.Phe983Ala 16489767:24:328
status: NEWX
ABCB1 p.Phe983Ala 16489767:24:330
status: NEW58 The recombinant baculovirus containing the Pgp mutant F983A [BV-MDR1-(H6)-F983A] was constructed in the same way as BV-MDR1-(H6) (25) using recombinant plasmid pBac- PakMDR1-(H6)-F983A.
X
ABCB1 p.Phe983Ala 16489767:58:54
status: NEWX
ABCB1 p.Phe983Ala 16489767:58:74
status: NEWX
ABCB1 p.Phe983Ala 16489767:58:179
status: NEW59 The NdeI-XhoI fragment of pTM1-MDR1-(H6)-F983A (containing the codon for amino acid phenylalanine 983 changed to that of alanine) (47) was cloned into the wild-type MDR1 coding region of plasmid pBacPak9-MDR1-(H6) to generate pBacPakMDR1-(H6)- F983A.
X
ABCB1 p.Phe983Ala 16489767:59:41
status: NEWX
ABCB1 p.Phe983Ala 16489767:59:42
status: NEW60 The recombinant baculovirus BV-MDR1(H6)-F983A was generated according to ref 25.
X
ABCB1 p.Phe983Ala 16489767:60:40
status: NEW61 For expression of the wild-type Pgp and the mutant F983A, cells were propagated to 80% confluency at 27 °C in the monolayer and infected with the recombinant baculoviruses with a multiplicity of infection of 10 and harvested after 72 h of infection.
X
ABCB1 p.Phe983Ala 16489767:61:51
status: NEW159 When dissociation of bound [125 I]IAAP in response to vanadate trapping was studied in the Pgp F983A mutant that is impaired in modulation by cis-(Z)-flupentixol (38, 39), no such delay in dissociation was observed even in the presence of 25 µM cis-(Z)-flupentixol (k ) 1.86 ( 0.25/ min, t1/2 ) 0.37 min) (R2 ) 0.99) (Figure 2C,D), suggesting that the inhibitory effect on substrate dissociation is dependent on a functional interaction of cis-(Z)-flupentixol with Pgp.
X
ABCB1 p.Phe983Ala 16489767:159:95
status: NEW171 Consistent with that, stimulation of ATP hydrolysis by 50 µM prazosin in the Pgp F983A mutant was minimally affected by cis-(Z)- flupentixol (25 µM) (Figure 3B, right), further supporting that the inhibitory effect on substrate-stimulated ATP hydrolysis is mediated through a specific interaction of cis- (Z)-flupentixol with the allosteric site of Pgp.
X
ABCB1 p.Phe983Ala 16489767:171:86
status: NEW187 Vanadate trapping of wild-type (top and middle panels) and F983A (bottom panel) Pgp was carried out in the presence (middle and lower panels) and absence (top panel) of 25 µM cis-(Z)-flupentixol, similar to the above experiment, except that nonradioactive 8-azido-ADP (1.25 mM) was used for trapping, and trapped samples were incubated and photo-cross-linked with 5 nM [125I]IAAP, a Pgp substrate.
X
ABCB1 p.Phe983Ala 16489767:187:59
status: NEW190 Key: no modulator, O; 25 µM cis-(Z)-flupentixol, b; 25 µM cis-(Z)-flupentixol in F983A, 0.
X
ABCB1 p.Phe983Ala 16489767:190:91
status: NEW207 The rate of ATP hydrolysis by the wild-type (left and middle histograms) and F983A (right histogram) Pgp was measured as mentioned in the presence of 50 µM prazosin and varying concentrations (0-50 µM) of the allosteric modulator cis-(Z)- flupentixol (left and right panels) or the competitive modulator verapamil (middle panel).
X
ABCB1 p.Phe983Ala 16489767:207:77
status: NEW221 Since the stimulatory effect on both substrate interaction and ATP hydrolysis is abrogated in the Pgp F983A mutant (38), which is impaired in modulation by cis-(Z)-flupentixol (38, 39), it suggests that both phenomena are mediated through modulator interaction at the allosteric site.
X
ABCB1 p.Phe983Ala 16489767:221:102
status: NEW238 The reduced effectiveness of cis-(Z)-flupentixol to inhibit the prazosin-stimulated ATP hydrolysis (Figure 3B, right) in the Pgp F983A mutant further confirms that the inhibitory action of the modulator is mediated through its interaction at the allosteric site of Pgp and not by its nonproductive (nonstimulating) association with the substrate site, blocking access to prazosin.
X
ABCB1 p.Phe983Ala 16489767:238:129
status: NEW245 The dissociation of bound [125 I]IAAP coupled to vanadate trapping was minimally affected by cis-(Z)-flupentixol in the Pgp F983A mutant (Figure 2C,D), further emphasizing the involvement of the allosteric modulator site in the phenomenon.
X
ABCB1 p.Phe983Ala 16489767:245:124
status: NEW252 In the Pgp F983A mutant, the stimulatory signal (for ATP hydrolysis) originating from the substrate site is minimally affected in the presence of cis-(Z)-flupentixol (Figure 3B, right); this suggests that the modulator-induced interference in cross talk between the FIGURE 5: Effect of cis-(Z)-flupentixol on dissociation of trapped [R-32P]-8-azido-ADP.
X
ABCB1 p.Phe983Ala 16489767:252:11
status: NEW
PMID: 16505485
[PubMed]
Maki N et al: "Allosteric modulation bypasses the requirement for ATP hydrolysis in regenerating low affinity transition state conformation of human P-glycoprotein."
No.
Sentence
Comment
50
Baculovirus Expression of Human Pgp-Recombinant baculoviruses BV-MDR1-(His6) (19) and BV-MDR1-(His6)-F983A (32) harboring the wild type and the Pgp F983A mutant, respectively, were used to infect High Five insect cells grown in Excell 400 medium as described (34).
X
ABCB1 p.Phe983Ala 16505485:50:101
status: NEWX
ABCB1 p.Phe983Ala 16505485:50:148
status: NEW86 No modulator-induced regeneration of the [125 I]IAAP binding was observed in the Pgp F983A mutant that is impaired in interaction with cis-(Z)-flupentixol (Fig. 1, A (bottom) and B).
X
ABCB1 p.Phe983Ala 16505485:86:85
status: NEW93 A, isolated membranes (0.1 mg/ml protein) from High Five insect cells, infected eitherwithrecombinantbaculovirusBV-MDR1(His6) or with BV-MDR1(His6)-F983A, were vanadate-trapped with 1.25 mM 8-azido-ATP (8-N3-ATP) and 0.25mM sodiumorthovanadate.Vanadate-trapped Pgp, either the wild type (top three panels) or the Pgp F983A mutant (bottom panel), in isolated membranes was pelleted, resuspended, and incubated in a vanadate- and nucleotide-free medium for the indicated time periods in the absence (second panel from top) and presence of either 1.25 mM 8-azido-ATP (top) or 25 M cis-(Z)-flupentixol (third panel from top and bottom panel), prior to photocross-linking with 5 nM [125 I]IAAP.
X
ABCB1 p.Phe983Ala 16505485:93:148
status: NEWX
ABCB1 p.Phe983Ala 16505485:93:317
status: NEW97 Solid bar, none; open bar, 1.25 mM 8-azido-ATP; hatched bar, 25 M cis-(Z)-flupentixol plus 0.25 mM EDTA; gray bar, F983A/25 M cis-(Z)-flupentixol plus 0.25 mM EDTA.
X
ABCB1 p.Phe983Ala 16505485:97:123
status: NEW
PMID: 17017890
[PubMed]
Tsakovska I et al: "Phenothiazines and structurally related compounds as modulators of cancer multidrug resistance."
No.
Sentence
Comment
76
It was demonstrated that a single substitution of alanine for phenylalanine at position 983 in the putative TM12 of Pgp markedly altered the ability of the stereoizomers to modulate ATP hydrolysis and [125 I] IAAP labeling of Pgp and also affected inhibition of Pgp-mediated transport by both isomers of flupentixol.
X
ABCB1 p.Phe983Ala 17017890:76:50
status: NEW
PMID: 17318783
[PubMed]
Fong WF et al: "Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes."
No.
Sentence
Comment
67
Baculovirus-mediated expression of human Pgp and photoaffinity labeling of Pgp with [125 I]IAAP High Five insect cells were transfected with a recombinant baculovirus harboring either the wild type {BV-MDR1-(H6)} [14] or the F983A mutant {BV-MDR1-F983A-(H6)} [15] human MDR1 cDNA [16].
X
ABCB1 p.Phe983Ala 17318783:67:225
status: NEWX
ABCB1 p.Phe983Ala 17318783:67:247
status: NEW123 To investigate the effect of SCH on Pgp substrate recognition, we performed photoaffinity labeling studies with [125 I]IAAP in insect cells transfected with either wild type or the F983A mutated Pgp.
X
ABCB1 p.Phe983Ala 17318783:123:181
status: NEW127 The inhibitory effect of SCH on [125 I]IAAP binding was unaltered in the F983A mutatant Pgp, indicating that this specific allosteric regulatory site was not involved in the inhibitory action of SCH.
X
ABCB1 p.Phe983Ala 17318783:127:73
status: NEW157 Lastly, SCH showed some inhibitory effects on [125 I]IAAP photo-labelling of Fig. 9 Effect of SCH on [125 I]IAAP binding to wild-type and to the F983A mutant of Pgp.
X
ABCB1 p.Phe983Ala 17318783:157:145
status: NEW158 Membrane preparations (15 mg of protein) containing wild-type Pgp (A) or the F983A mutant (B) were photoaffinity labeled with 5nM [125 I]IAAP in the presence of varying concentrations (0±100 mM) of SCH.
X
ABCB1 p.Phe983Ala 17318783:158:77
status: NEW
PMID: 9819232
[PubMed]
Hafkemeyer P et al: "Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein."
No.
Sentence
Comment
8
The V981A and F983A double mutant showed the most effect on transport of fluorescent substrates.
X
ABCB1 p.Phe983Ala 9819232:8:14
status: NEW50 Moreover, double mutants based on the triple mutant were cloned (L975A-V981A-F983, L975A-V981-F983A, L975- V981A-F983A).
X
ABCB1 p.Phe983Ala 9819232:50:94
status: NEWX
ABCB1 p.Phe983Ala 9819232:50:113
status: NEW98 Alanine mutants were arranged in such a way that three alanine mutations were putatively located in the outer plasma membrane leaflet (L975A, V981A, and F983A) and four in the inner leaflet (M986A, V988A, Q990A, and V991A), assuming an R-helical structure to TM 12 (Figure 1b).
X
ABCB1 p.Phe983Ala 9819232:98:153
status: NEW124 Double mutants combining pairwise L975A, V981A, and F983A were constructed in order to determine the critical nonconserved residues that were responsible for mediating drug transport in the amino-proximal half of TM 12.
X
ABCB1 p.Phe983Ala 9819232:124:52
status: NEW125 Those double mutants were L975A-V981A, L975A-F983A, and V981A-F983A.
X
ABCB1 p.Phe983Ala 9819232:125:45
status: NEWX
ABCB1 p.Phe983Ala 9819232:125:62
status: NEW126 The V981-F983 double mutant was Table 1: Properties of Wild-Type and Mutant P-glycoproteinsa drug transporta cell surface expressionc rhodamine daunomycin bodipy-verapamil calcein-AM bodipy-taxol wild-type ++++ ++++ ++++ ++++ ++++ ++++ L975A ++++ ++++ ++++ ++++ ++++ ++++ V981A ++++ ++++ ++++ ++++ ++++ ++++ F983A ++++ ++++ ++++ ++++ ++++ ++++ M986A ++++ ++++ n.d. ++++ ++++ n.d. V988A ++++ ++++ n.d. ++++ ++++ n.d. Q990A ++++ ++++ n.d. ++++ ++++ n.d. V991A ++++ ++++ n.d. ++++ ++++ n.d. L975A, V981A, F983A ++++ no transport no transport ++ ++ ++ M986A, V988A, Q990A, V991A ++++ ++++ +++ ++ ++++ ++++ V981A, F983A ++++ + no transport ++ ++ +++ L975A, F983A ++++ + ++ ++++ +++ ++++ L975A, V981A ++++ ++ no transport ++++ +++ ++++ a Symbols are noted as follows: ++++, wild-type activity; ++, impaired activity; +, residual activity; and n.d., not determined. b Drug transport was determined by FACS.
X
ABCB1 p.Phe983Ala 9819232:126:308
status: NEWX
ABCB1 p.Phe983Ala 9819232:126:502
status: NEWX
ABCB1 p.Phe983Ala 9819232:126:609
status: NEWX
ABCB1 p.Phe983Ala 9819232:126:652
status: NEW130 Mutant Pgp`s are the triple mutant in the amino-proximal half of TM 12 (L975A-V981A-F983A, - -), the quadruple mutant in the carboxy-terminal half of TM 12 (M986A-V988A-Q990A-V991A, ‚‚‚), the double mutants L975A-V981A (- - -), L975A-F983A (-‚‚-), and V981A-F983A (-‚-).
X
ABCB1 p.Phe983Ala 9819232:130:84
status: NEWX
ABCB1 p.Phe983Ala 9819232:130:255
status: NEWX
ABCB1 p.Phe983Ala 9819232:130:293
status: NEW134 The double mutants involving L975A and either V981A and/or F983A were still capable of transporting calcein-AM, bodipy-taxol, and bodipy-verapamil but rhodamine 123 and daunorubicin transport was significantly reduced compared to wild-type Pgp (Figure 4), indicating a significant contribution of L975 to drug specificity.
X
ABCB1 p.Phe983Ala 9819232:134:59
status: NEW141 Mutant Pgp`s are the triple mutant in the amino-proximal half of TM 12 (L975A-V981A-F983A) and the quadruple mutant (M986A-V988A-Q990A-V991A) (s).
X
ABCB1 p.Phe983Ala 9819232:141:84
status: NEW144 Photoaffinity labeling demonstrated that the triple mutant L975A-V981A-F983A displayed a significant reduction in binding of IAAP compared to wild-type Pgp which is consistent with its reduced drug transport ability (Figure 5b).
X
ABCB1 p.Phe983Ala 9819232:144:71
status: NEW147 The three double mutants L975A-V981A, L975A-F983A, and V981A-F983A were able to bind IAAP but somewhat less than wild-type Pgp as was also true for the single mutants investigated in this study (Figure 5b,c).
X
ABCB1 p.Phe983Ala 9819232:147:44
status: NEWX
ABCB1 p.Phe983Ala 9819232:147:61
status: NEW153 Mutant MDR1s are double mutants L975A-V981A, L975A-F983A, and V981A-F983A (s).
X
ABCB1 p.Phe983Ala 9819232:153:51
status: NEWX
ABCB1 p.Phe983Ala 9819232:153:68
status: NEW159 ATP binding was equivalent for wild-type MDR1 and the MDR1 mutants L975A-V981A-F983A as well as for M986A-V988A-Q990A-V991A (Figure 7).
X
ABCB1 p.Phe983Ala 9819232:159:79
status: NEW162 Vanadate-trapped [R-32P]-8-azido-ADP was significantly reduced in the triple mutant L975A-V981A-F983A (Figure 8b,c), consistent with the decrease a b c FIGURE 5: Photoaffinity labeling of wild-type and mutant Pgp`s.
X
ABCB1 p.Phe983Ala 9819232:162:96
status: NEW174 (a) pTM: cells infected with vTF 7-3 virus and transfected with the expression vector containing no MDR1 (pTM1) (negative control), WT (wild-type human MDR1), and mutant Pgp`s are the triple mutant in the amino-proximal half of TM 12 (L975A-V981A-F983A) and the quadruple mutant in the carboxy-terminal half of TM 12 (M986A- V988A-Q990A-V991A).
X
ABCB1 p.Phe983Ala 9819232:174:247
status: NEW176 Mutant MDR1s are the three double mutants L975A-V981A, L975A-F983A, and V981A-F983A.
X
ABCB1 p.Phe983Ala 9819232:176:61
status: NEWX
ABCB1 p.Phe983Ala 9819232:176:78
status: NEW188 pTM: cells infected with vTF 7-3 virus and transfected with the expression vector containing no MDR1 (pTM1) (negative control), WT (wild-type human MDR1), the triple mutant in the amino-proximal half of TM 12 (L975A-V981A-F983A), the quadruple mutant in the carboxy-terminal half of TM 12 (M986A- V988A-Q990A-V991A), WT (wild-type human MDR1) in the presence of 250 µM EDTA and without MgCl2 to assess the specificity of the 170 kDa band representing Pgp as indicated with the arrow.
X
ABCB1 p.Phe983Ala 9819232:188:222
status: NEW193 (Middle panel) Vanadate-induced [R-32P]-8-azido-ADP labeling was performed at 37 °C. pTM: cells infected with vTF 7-3 virus and transfected with the expression vector containing no MDR1 (pTM1) (negative control), WT (wild-type human MDR1), the triple mutant in the amino-proximal half of TM 12 (L975A-V981A-F983A), and the quadruple mutant in the carboxy-terminal half of TM 12 (M986A- V988A-Q990A-V991A).
X
ABCB1 p.Phe983Ala 9819232:193:312
status: NEW227 To determine which combinations of these three residues of TM 12 predicted to lie in the outer leaflet were responsible for the loss of transport activity, we constructed double mutants (L975A-V981A, L975A-F983A, and V981A-F983A).
X
ABCB1 p.Phe983Ala 9819232:227:206
status: NEWX
ABCB1 p.Phe983Ala 9819232:227:223
status: NEW228 The double mutants showed reduced drug transport suggesting that a change in any two of these three amino Table 2: Properties of Wild-Type and Mutant P-Glycoproteinsa photoaffinity labelinga ATP bindingb ATPase activityc wild-type ++++ ++++ ++++ L975A +++ n.d. +++ V981A +++ n.d. +++ F983A +++ n.d. +++ M986A n.d. n.d. n.d. V988A n.d. n.d. n.d. Q990A n.d. n.d. n.d. V991A n.d. n.d. n.d. L975A,V981A, F983A + ++++ + M986A, V988A, Q990A, V991A ++ ++++ ++ V981A, F983A +++ n.d. +++ L975A, F983A +++ n.d. +++ L975A, V981A +++ n.d. +++ a Symbols are noted as follows: ++++, wild-type activity; ++, impaired activity; +, residual activity; and n.d. not determined. b Photoaffinity labeling was done in HeLa crude membrane preparations using [125 I]iodoarylazidoprazosin.
X
ABCB1 p.Phe983Ala 9819232:228:284
status: NEWX
ABCB1 p.Phe983Ala 9819232:228:400
status: NEWX
ABCB1 p.Phe983Ala 9819232:228:460
status: NEWX
ABCB1 p.Phe983Ala 9819232:228:486
status: NEW236 While no single residue is crucial, combinations of residues, especially V981A and F983A, affect binding of specific substrates such as daunomycin and rhodamine 123.
X
ABCB1 p.Phe983Ala 9819232:236:83
status: NEW248 F983A in combination with the other substitutions was also found to have a major effect on fluorescent drug transport.
X
ABCB1 p.Phe983Ala 9819232:248:0
status: NEW
PMID: 11557524
[PubMed]
Ito K et al: "Single amino acid substitution of rat MRP2 results in acquired transport activity for taurocholate."
No.
Sentence
Comment
199
Dey et al. (5) demonstrated that the transport activity of the F983A mutant of P-glycoprotein was the same as that of wild-type P-glycoprotein, whereas the susceptibility of F983A to the stimulatory and inhibitory effect of cis- and trans-flupentixol, respectively, was markedly reduced compared with that of wild-type P-glycoprotein.
X
ABCB1 p.Phe983Ala 11557524:199:63
status: NEWX
ABCB1 p.Phe983Ala 11557524:199:174
status: NEW
PMID: 22360349
[PubMed]
Mandal D et al: "Evidence for modulatory sites at the lipid-protein interface of the human multidrug transporter P-glycoprotein."
No.
Sentence
Comment
28
The desired nucleotide replacements were confirmed by Big-Dye version 3.1 (BD Sciences) nucleotide sequencing of the MDR1 open reading frame in recombinant plasmids pKM2-MDR1- V715A, -F716A, -I719A, -G723A, -I764A, -I765A, -I768A, -F770A, -L772A, -T837A, -I840A, -I864A, -I867A, -A871F, -T945A, -M948A, -F983A, -M986A, -V988A, -Q990A, and -V991A.
X
ABCB1 p.Phe983Ala 22360349:28:304
status: NEW102 A comparable level of basal binding of [125 I]IAAP to wild-type Pgp and Pgp mutants M948A, F983A, V988A, M986A, and Q990A (Figure 2B) rules out the possibility that the reduced level of stimulation in the mutants is due to loss of [125 I]IAAP binding and not stimulation per se. To investigate whether M948, Q990, F983, M986, and V988 are part of a general module involved in the regulation of substrate binding or are molecular components specific to cis- (Z)-flupentixol, we studied the effect of a structurally unrelated Pgp modulator, cyclosporin A, on binding of [125 I]IAAP to all 21 mutants.
X
ABCB1 p.Phe983Ala 22360349:102:91
status: NEW110 Stimulation of ATP Hydrolysis by cis-(Z)-Flupentixol and Verapamil cis-(Z)-flupentixol-mediated stimulation verapamil-mediated stimulation maximal stimulation (x-fold basal) concentration for half-maximal stimulation (μM) remark maximal stimulation (x-fold basal) concentration for half-maximal stimulation (μM) remark WT 7.3 ± 0.4 6.8 ± 1.5 5.6 ± 0.19 6.6 ± 1.04 V715A 6.2 ± 0.2 5.0 ± 0.9 6.4 ± 0.37 16.3 ± 3.3 V716A 5.1 ± 0.2 4.7 ± 1.1 NDb NDb a I719A 4.6 ± 0.08 4.7 ± 0.4 5.8 ± 0.26 6.5 ± 1.31 G723A 5.3 ± 0.3 10.93 ± 2.7 5.4 ± 0.1 11.6 ± 0.88 I764A 4.5 ± 0.4 4.1 ± 2 3.2 ± 0.26 27.9 ± 8.4 I765A 4.96 ± 0.2 2.3 ± 0.47 NDb NDb a I768A 4.8 ± 0.2 1.2 ± 0.43 4.8 ± 0.19 8.5 ± 1.4 F770A 6.6 ± 0.6 10.9 ± 3.9 8.6 ± 0.59 13.2 ± 3.2 L772A 3.6 ± 0.2 2.96 ± 0.9 3.2 ± 0.11 9.5 ± 1.6 T837A 1.1 ± 0.06 NDb a 2.6 ± 0.1 3.1 ± 0.9 I840A 4.0 ± 0.3 25.6 ± 6.5 6.9 ± 0.2 13.5 ± 0.5 I864A 0.6 ± 0.05 NDb a 4.1 ± 0.25 0.9 ± 1.04 I867A 10.2 ± 1.3 72.3 ± 18.5 10.2 ± 0.52 30.7 ± 3.1 A871F NDb NDb NDb NDb a T945A 5.0 ± 0.3 13.7 ± 3.1 6.4 ± 0.15 6.9 ± 0.71 M948A NDb NDb a 6.8 ± 1.5 44.4 ± 12.4 F983A 4.95 ± 0.36 19.59 ± 5.0 6.1 ± 0.38 6.6 ± 1.8 M986A 3.8 ± 0.3 2.6 ± 1.5 7.7 ± 0.76 30.0 ± 8.6 V988A 3.0 ± 0.2 21.4 ± 7.6 6.5 ± 0.31 16.9 ± 2.9 Q990A 1.8 ± 0.4 18.9 ± 2.6 a 7.7 ± 0.58 12.9 ± 3.7 V991A 3.9 ± 0.2 21.1 ± 5.0 5.9 ± 0.59 21.9 ± 7.2 a Mutants with <2-fold maximal stimulation (<25% of the wild-type level).
X
ABCB1 p.Phe983Ala 22360349:110:1367
status: NEW224 Substitutions F983A, M986A, and V988A completely abrogate stimulation of substrate binding (Figure 2) with only modest effects on ATP-site stimulation (Figure 4), which indicates that the two modulatory events are not tightly coupled to each other.
X
ABCB1 p.Phe983Ala 22360349:224:14
status: NEW
PMID: 16889754
[PubMed]
Wan CK et al: "Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells."
No.
Sentence
Comment
113
Baculovirus mediated expression of human Pgp and photoaffinity labeling of Pgp with [125 I]IAAP Recombinant baculoviruses harboring either the wild type BV-MDR1-(H6) [24] or the F983A mutant BV-MDR1-F983A- (H6)[25] of human MDR1 cDNA, with 6 Â His-tag at the C-terminal end, were used to infect High Five insect cells grown in serum free Excell 400 medium as described [26].
X
ABCB1 p.Phe983Ala 16889754:113:178
status: NEWX
ABCB1 p.Phe983Ala 16889754:113:199
status: NEW216 To understand whether F983 has any role in the interaction of gomisin A with Pgp, we studied [125 I]IAAP labeling of Pgp F983A mutant in the presence of varying concentrations of gomisin A.
X
ABCB1 p.Phe983Ala 16889754:216:121
status: NEW237 b i o c h e m i c a l p h a r m a c o l o g y 7 2 ( 2 0 0 6 ) 8 2 4 - 8 3 7 835 Fig. 10 - Effect of gomisin A on [125 I]IAAP photo-labeling of the wild type and F983A mutant Pgp.
X
ABCB1 p.Phe983Ala 16889754:237:161
status: NEW238 Wild type (Fig. 10A, top panel) or F983A mutant (Fig. 10B, bottom panel) Pgp in isolated membranes was photoaffinity labeled with 5 nM of [125 I]IAAP in the presence of varying concentrations (0-100 mM) of gomisin A (GOM).
X
ABCB1 p.Phe983Ala 16889754:238:35
status: NEWX
ABCB1 p.Phe983Ala 16889754:238:161
status: NEW246 However, gomisin A`s effect on [125 I]IAAP labeling of Pgp was not altered in the Pgp F983A mutant that is impaired of modulation by cis- (Z)-flupentixol.
X
ABCB1 p.Phe983Ala 16889754:246:86
status: NEW112 Baculovirus mediated expression of human Pgp and photoaffinity labeling of Pgp with [125 I]IAAP Recombinant baculoviruses harboring either the wild type BV-MDR1-(H6) [24] or the F983A mutant BV-MDR1-F983A- (H6)[25] of human MDR1 cDNA, with 6 His-tag at the C-terminal end, were used to infect High Five insect cells grown in serum free Excell 400 medium as described [26].
X
ABCB1 p.Phe983Ala 16889754:112:178
status: NEWX
ABCB1 p.Phe983Ala 16889754:112:199
status: NEW217 To understand whether F983 has any role in the interaction of gomisin A with Pgp, we studied [125 I]IAAP labeling of Pgp F983A mutant in the presence of varying concentrations of gomisin A.
X
ABCB1 p.Phe983Ala 16889754:217:121
status: NEW239 Wild type (Fig. 10A, top panel) or F983A mutant (Fig. 10B, bottom panel) Pgp in isolated membranes was photoaffinity labeled with 5 nM of [125 I]IAAP in the presence of varying concentrations (0-100 mM) of gomisin A (GOM).
X
ABCB1 p.Phe983Ala 16889754:239:35
status: NEW247 However, gomisin A`s effect on [125 I]IAAP labeling of Pgp was not altered in the Pgp F983A mutant that is impaired of modulation by cis- (Z)-flupentixol.
X
ABCB1 p.Phe983Ala 16889754:247:86
status: NEW
PMID: 16729976
[PubMed]
Maki N et al: "Biochemical and pharmacological properties of an allosteric modulator site of the human P-glycoprotein (ABCB1)."
No.
Sentence
Comment
47
Replacement of the F983 with alanine (F983A) abrogates inhibition of [125 I]IAAP transport as well as stimulation of Pgp-[125 I]IAAP interaction by cis-(Z)-flupentixol, without any effect on the basal level of [125 I]IAAP binding and transport by Pgp [25].
X
ABCB1 p.Phe983Ala 16729976:47:38
status: NEW59 Previously characterized [25] mouse NIHMDR1-WT and NIHMDR1-F983A cells were used for the studies with intact cells.
X
ABCB1 p.Phe983Ala 16729976:59:59
status: NEW118 Replacement of F983 by an alanine (F983A) abrogates both stimulation of [125 I]IAAP binding to Pgp as well as inhibition of transport by cis-(Z)- flupentixol [25].
X
ABCB1 p.Phe983Ala 16729976:118:35
status: NEW120 We studied [125 I]IAAP binding to the wild type Pgp as well as to the Pgp F983A mutant in NIHMDR1-WT and NIHMDR1-F983A cells, respectively, in the presence of several Pgp modulators, both structurally related (Fig. 1A and B) and unrelated (Fig. 1C) to cis-(Z)-flupentixol.
X
ABCB1 p.Phe983Ala 16729976:120:74
status: NEWX
ABCB1 p.Phe983Ala 16729976:120:113
status: NEW121 A detectable level of [125 I]IAAP binding to the wild type and the Pgp F983A mutant was observed (Fig. 2A-C, autoradiogram, none) in the absence of any modulator.
X
ABCB1 p.Phe983Ala 16729976:121:71
status: NEWX
ABCB1 p.Phe983Ala 16729976:121:74
status: NEW122 The relatively lower level of [125 I]IAAP signal in the Pgp F983A mutant was due to a reduced level of the expression of the mutant Pgp in NIHMDR1-F983A cells, as determined by immunoblotting with a Pgp specific antibody PEPG13 (see immunoblots).
X
ABCB1 p.Phe983Ala 16729976:122:60
status: NEWX
ABCB1 p.Phe983Ala 16729976:122:71
status: NEWX
ABCB1 p.Phe983Ala 16729976:122:147
status: NEW123 As evident in Fig. 2A, thioxanthene derivatives cis-(Z)-clopentixol, trans-(E)-clopentixol, cis-(Z)- 753, compound 789, cis-(Z)-768, and trans-(E)-768, all stimulated [125 I]IAAP binding to the wild type Pgp (autoradiogram, upper panel), and the stimulatory effect was abrogated in the Pgp F983A mutant (autoradiogram, lower panel).
X
ABCB1 p.Phe983Ala 16729976:123:60
status: NEWX
ABCB1 p.Phe983Ala 16729976:123:147
status: NEWX
ABCB1 p.Phe983Ala 16729976:123:290
status: NEW127 The inhibitory potential of these compounds on [125 I]IAAP binding remained unaltered in the Pgp F983A mutant (Fig. 2C, autoradiogram, lower panel), suggesting no involvement of F983 in the modulation of Pgp function by those compounds.
X
ABCB1 p.Phe983Ala 16729976:127:97
status: NEW159 b i o c h e m i c a l p h a r m a c o l o g y 7 2 ( 2 0 0 6 ) 1 4 5 - 1 5 5150 Fig. 2 - (A) Effect of thioxanthenes on Pgp-[125 I]IAAP interaction in NIHMDR1-WT (wild type) and NIHMDR1-F983A (mutant F983A) cells.
X
ABCB1 p.Phe983Ala 16729976:159:185
status: NEWX
ABCB1 p.Phe983Ala 16729976:159:199
status: NEW161 Following incubation, cells were exposed to UV irradiation for 5 min, lysed, and resolved by SDS-PAGE (80,000 cells per well) as indicated in Section 2; (B) effect of phenothiazines on Pgp-[125 I]IAAP interaction in NIHMDR1-WT (wild type) and NIHMDR1-F983A (mutant F983A) cells. Experiment was done as described for (A), except that the modulators added were 5 mM cyclosporin A (CsA) (lane 2), 10 mM promethazine (lane 3), 10 mM chlorpromazine (lane 4), 10 mM trifluperazine (lane 5), 10 mM thioridazine (lane 6), or 1% DMSO (none) (lane 1); (C) effect of other modulators on Pgp- [125 I]IAAP interaction in NIHMDR1-WT (wild type) and NIHMDR1-F983A (mutant F983A) cells. Experiment was done exactly the same way as described in (A), except modulators used were 5 mM cyclosporin A (CsA) (lane 2), 5 mM rapamycin (lane 3), 10 mM nicardipine (lane 4), 10 mM niguldipine (lane 5), or in the absence of any modulator (none) (lane 1).
X
ABCB1 p.Phe983Ala 16729976:161:251
status: NEWX
ABCB1 p.Phe983Ala 16729976:161:265
status: NEWX
ABCB1 p.Phe983Ala 16729976:161:643
status: NEWX
ABCB1 p.Phe983Ala 16729976:161:657
status: NEW209 The stimulatory effect on [125 I]IAAP binding, and its abrogation in the Pgp F983A mutant, provided us with a convenient assay to study the specificity of the allosteric site.
X
ABCB1 p.Phe983Ala 16729976:209:77
status: NEW119 Replacement of F983 by an alanine (F983A) abrogates both stimulation of [125 I]IAAP binding to Pgp as well as inhibition of transport by cis-(Z)- flupentixol [25].
X
ABCB1 p.Phe983Ala 16729976:119:35
status: NEW124 As evident in Fig. 2A, thioxanthene derivatives cis-(Z)-clopentixol, trans-(E)-clopentixol, cis-(Z)- 753, compound 789, cis-(Z)-768, and trans-(E)-768, all stimulated [125 I]IAAP binding to the wild type Pgp (autoradiogram, upper panel), and the stimulatory effect was abrogated in the Pgp F983A mutant (autoradiogram, lower panel).
X
ABCB1 p.Phe983Ala 16729976:124:290
status: NEW128 The inhibitory potential of these compounds on [125 I]IAAP binding remained unaltered in the Pgp F983A mutant (Fig. 2C, autoradiogram, lower panel), suggesting no involvement of F983 in the modulation of Pgp function by those compounds.
X
ABCB1 p.Phe983Ala 16729976:128:97
status: NEW160 b i o c h e m i c a l p h a r m a c o l o g y 7 2 ( 2 0 0 6 ) 1 4 5 - 1 5 5 150 Fig. 2 - (A) Effect of thioxanthenes on Pgp-[125 I]IAAP interaction in NIHMDR1-WT (wild type) and NIHMDR1-F983A (mutant F983A) cells.
X
ABCB1 p.Phe983Ala 16729976:160:186
status: NEWX
ABCB1 p.Phe983Ala 16729976:160:200
status: NEW162 Following incubation, cells were exposed to UV irradiation for 5 min, lysed, and resolved by SDS-PAGE (80,000 cells per well) as indicated in Section 2; (B) effect of phenothiazines on Pgp-[125 I]IAAP interaction in NIHMDR1-WT (wild type) and NIHMDR1-F983A (mutant F983A) cells. Experiment was done as described for (A), except that the modulators added were 5 mM cyclosporin A (CsA) (lane 2), 10 mM promethazine (lane 3), 10 mM chlorpromazine (lane 4), 10 mM trifluperazine (lane 5), 10 mM thioridazine (lane 6), or 1% DMSO (none) (lane 1); (C) effect of other modulators on Pgp- [125 I]IAAP interaction in NIHMDR1-WT (wild type) and NIHMDR1-F983A (mutant F983A) cells. Experiment was done exactly the same way as described in (A), except modulators used were 5 mM cyclosporin A (CsA) (lane 2), 5 mM rapamycin (lane 3), 10 mM nicardipine (lane 4), 10 mM niguldipine (lane 5), or in the absence of any modulator (none) (lane 1).
X
ABCB1 p.Phe983Ala 16729976:162:251
status: NEWX
ABCB1 p.Phe983Ala 16729976:162:265
status: NEWX
ABCB1 p.Phe983Ala 16729976:162:643
status: NEWX
ABCB1 p.Phe983Ala 16729976:162:657
status: NEW210 The stimulatory effect on [125 I]IAAP binding, and its abrogation in the Pgp F983A mutant, provided us with a convenient assay to study the specificity of the allosteric site.
X
ABCB1 p.Phe983Ala 16729976:210:77
status: NEW
PMID: 16624245
[PubMed]
Ghosh P et al: "Allosteric modulation of the human P-glycoprotein involves conformational changes mimicking catalytic transition intermediates."
No.
Sentence
Comment
3
The protection by Xupentixol is abolished in the Pgp F983A mutant that is impaired in modulation by Xupentixols, indicating involvement of the allosteric site in generating the conformational change.
X
ABCB1 p.Phe983Ala 16624245:3:53
status: NEW46 Baculovirus mediated expression of human Pgp A recombinant baculovirus harboring either the wild-type or the F983A mutant human MDR1 cDNA, with 6 £His-tag at the C-terminal end, BV-MDR1-(H6) [34] was used to infect High Five insect cells grown in serum free Excell 400 medium as described [35].
X
ABCB1 p.Phe983Ala 16624245:46:109
status: NEW105 SigniWcantly, no detectable protection from trypsin digestion was observed for the Pgp F983A mutant (Fig. 2C) that is impaired in modulation by Xupentixol [21].
X
ABCB1 p.Phe983Ala 16624245:105:87
status: NEW112 Protection to limited trypsin digestion is induced by both isomers of Xupentixol, which is aVected in Pgp F983A mutant.
X
ABCB1 p.Phe983Ala 16624245:112:106
status: NEW116 (C) Similar experiments were carried out with the Pgp F983A mutant in the presence of varying concentrations (0-25 M) of cis-(Z)-Xupentixol and resolved as stated above.
X
ABCB1 p.Phe983Ala 16624245:116:54
status: NEW117 198 49.8 115 93 +-Trypsin 0 1 2.5 5 10cis-(Z)-Flupentixol (µM) 250 Wild Type 198 49.8 115 93 +-Trypsin 0 1 2.5 5 10trans-(E)-Flupentixol (µM) 250 Wild Type 198 49.8 115 93 +-Trypsin 0 1 2.5 5 10cis-(Z)-Flupentixol (µM) 250 F983A A B C strate site, both isomers of Xupentixol induced similar conformational changes in Pgp.
X
ABCB1 p.Phe983Ala 16624245:117:238
status: NEW188 Since the Pgp F983A mutant that is impaired in modulation by Xupentixol [21,22] displays no such protection (Fig. 2C) the functional signiWcance of the conformational change in the mechanism of modulation is underscored.
X
ABCB1 p.Phe983Ala 16624245:188:14
status: NEW223 Consistent with that, in the Pgp F983A mutant, the loss of cis-(Z)-Xupentixol-induced conformational change coincides with impaired modulation of [125 I]IAAP binding, whereas inhibition of [125 I]IAAP binding by cyclosporin A remained unaltered in the mutant [21].
X
ABCB1 p.Phe983Ala 16624245:223:33
status: NEW107 SigniWcantly, no detectable protection from trypsin digestion was observed for the Pgp F983A mutant (Fig. 2C) that is impaired in modulation by Xupentixol [21].
X
ABCB1 p.Phe983Ala 16624245:107:87
status: NEW114 Protection to limited trypsin digestion is induced by both isomers of Xupentixol, which is aVected in Pgp F983A mutant.
X
ABCB1 p.Phe983Ala 16624245:114:106
status: NEW118 (C) Similar experiments were carried out with the Pgp F983A mutant in the presence of varying concentrations (0-25 M) of cis-(Z)-Xupentixol and resolved as stated above.
X
ABCB1 p.Phe983Ala 16624245:118:54
status: NEW119 198 49.8 115 93 + - Trypsin 0 1 2.5 5 10 cis-(Z)-Flupentixol (&#b5;M) 25 0 Wild Type 198 49.8 115 93 + - Trypsin 0 1 2.5 5 10 trans-(E)-Flupentixol (&#b5;M) 25 0 Wild Type 198 49.8 115 93 + - Trypsin 0 1 2.5 5 10 cis-(Z)-Flupentixol (&#b5;M) 25 0 F983A A B C strate site, both isomers of Xupentixol induced similar conformational changes in Pgp.
X
ABCB1 p.Phe983Ala 16624245:119:247
status: NEW190 Since the Pgp F983A mutant that is impaired in modulation by Xupentixol [21,22] displays no such protection (Fig. 2C) the functional signiWcance of the conformational change in the mechanism of modulation is underscored.
X
ABCB1 p.Phe983Ala 16624245:190:14
status: NEW225 Consistent with that, in the Pgp F983A mutant, the loss of cis-(Z)-Xupentixol-induced conformational change coincides with impaired modulation of [125 I]IAAP binding, whereas inhibition of [125 I]IAAP binding by cyclosporin A remained unaltered in the mutant [21].
X
ABCB1 p.Phe983Ala 16624245:225:33
status: NEW
PMID: 16545467
[PubMed]
Shilling RA et al: "New light on multidrug binding by an ATP-binding-cassette transporter."
No.
Sentence
Comment
58
Although mutation of only one of these residues (L975A, V981A and F983A) has no effect on the phenotype of the protein [20], double mutations either completely inhibit (V981A/F983A and L975A/V981A) or cause 50% inhibition (L975A/F983A) of Table 1.
X
ABCB1 p.Phe983Ala 16545467:58:66
status: NEWX
ABCB1 p.Phe983Ala 16545467:58:175
status: NEWX
ABCB1 p.Phe983Ala 16545467:58:229
status: NEWX
ABCB1 p.Phe983Ala 16545467:58:740
status: NEW59 Published mutations in human and murine P-glycoprotein that alter drug transport in cells Location of mutation Mutation Refs Mutation Refs Mutation Refs Transmembrane helices H61A and others [14] I214L [60] L868W [59] G64R [15] P223A [65] I936A [21] L65R [15] S224P [60] F938A [21] Q139[H/P/R] [60] I306R [18] S939[A/C/T/Y/W/D/F] [21,22] G141V [17] F335A [16] T941A [21] G185V [61,62] V338A [66] Q942A [21] I186N [61] G338A [67,68] A943G [21] G187V [17] A339P [67,68] Y946A [21] G187E [60] G341A [66] S948A [21] A192T [60] S344[A/T/C/Y] [66] Y949A [21] F200L [60] N350I [19] C952A [21] F204S [60] P709A [65] F953A [21] R206L [60] G830V [17] L975A [20] W208G [60] I837L [23] F978A [16] K209E [60] N839I [23] V981A [20] L210I [60] I862F [19] F983A [20] T211P [60] L865F [19] F978A [16] V213A [60] P866A [65] N988D [59] Intracellular domain T169I [60] K177I [60] G288V [17] R170L [60] E180G [60] A931T [19] L171P [60] G181R [60] F934A [21] T172P [60] G183D [60] G935A [21] S176P [60] D184N [60] NBD D555N [63] K1076M [69] E1197Q [64] D558N [64] D1093N [64] D1203N [64] D592N [64] E1125Q [64] D1237N [64] E604Q [64] S1173A [70] E1249Q [64] Review TRENDS in Pharmacological Sciences Vol.27 No.
X
ABCB1 p.Phe983Ala 16545467:59:48
status: NEWX
ABCB1 p.Phe983Ala 16545467:59:109
status: NEWX
ABCB1 p.Phe983Ala 16545467:59:740
status: NEW61 The same mutations have either no effect (L975A/F983A and L975A/V981A) or cause up to 50% inhibition (V981A/ F983A) in the transport of bodipy-verapamil, calcein-AM and bodipy-taxol.
X
ABCB1 p.Phe983Ala 16545467:61:48
status: NEWX
ABCB1 p.Phe983Ala 16545467:61:109
status: NEW57 Although mutation of only one of these residues (L975A, V981A and F983A) has no effect on the phenotype of the protein [20], double mutations either completely inhibit (V981A/F983A and L975A/V981A) or cause 50% inhibition (L975A/F983A) of Table 1.
X
ABCB1 p.Phe983Ala 16545467:57:66
status: NEWX
ABCB1 p.Phe983Ala 16545467:57:175
status: NEWX
ABCB1 p.Phe983Ala 16545467:57:229
status: NEW
PMID: 11428917
[PubMed]
Hrycyna CA et al: "Molecular genetic analysis and biochemical characterization of mammalian P-glycoproteins involved in multidrug resistance."
No.
Sentence
Comment
27
List of mutations in human, mouse and hamster P-gp`s that affect substrate specificity f aaa Mutation Regionb Sourcec Reference aa 78-97 EC 1 human MDR1 78 (ABC20)d Q128He TM 2 mouse mdr3 79 R138H IC 1 mouse mdr3 79 Q139H, R IC 1 mouse mdr3 79 G141V IC 1 human MDR1 25,80 Q145H IC 1 mouse mdr3 79 E155G, K IC 1 mouse mdr3 79 F159I IC 1 mouse mdr3 79 D174G IC 1 mouse mdr3 79 S176F, P IC 1 mouse mdr3 79 K177I IC 1 mouse mdr3 79 N179S IC1 mouse mdr3 79 N183S/G185V IC 1 human MDR1 81 G183D IC1 mouse mdr3 79 G185V IC 1 human MDR1 82-84 G187V IC 1 human MDR1 80 A192T TM 3 mouse mdr3 79 F204S EC 2 mouse mdr3 79 W208G EC 2 mouse mdr3 79 K209E EC 2 mouse mdr3 79 L210I TM 4 mouse mdr3 79 T211P TM 4 mouse mdr3 79 I214T TM 4 mouse mdr3 79 P223A TM 4 human MDR1 85 K285T IC 2 human MDR1 1 G288V IC 2 human MDR1 80 I299M, T319S, L322I, TM 5, EC3, IC 3 human MDR1 86 G324K, S351N V334 TM 6 human MDR1 1 F335A TM 6 human MDR1 25 F335 TM 6 human MDR1 87 V338A TM 6 human MDR1 88 G338A, A339P TM 6 hamster PGY 1 89,90 A339P TM 6 hamster PGY 1 90 G341V TM 6 human MDR1 88 K536R,Q N-NBD human MDR1 91 ERGA→DKGT N-NBD mouse mdr3 92 (aa 522-525) T578C N-NBD mouse mdr3 92 G812V IC 4 human MDR1 80 G830V IC 4 human MDR1 25,80 P866A TM 10 human MDR1 85 F934A TM 11 mouse mdr3 93 G935A TM 11 mouse mdr3 93 I936A TM 11 mouse mdr3 93 F938A TM 11 mouse mdr3 93 S939A TM 11 mouse mdr3 93 S939F TM 11 mouse mdr3 94,95 S941F TM 11 mouse mdr1 94,95 T941A TM 11 mouse mdr3 93 Q942A TM 11 mouse mdr3 93 Table 1-continued aaa Mutation Regionb Sourcec Reference A943G TM 11 mouse mdr3 93 Y946A TM 11 mouse mdr3 93 S948A TM 11 mouse mdr3 93 Y949A TM 11 mouse mdr3 93 C952A TM 11 mouse mdr3 93 F953A TM 11 mouse mdr3 93 F983A TM 12 human MDR1 96 L975A, V981A, F983A TM 12 human MDR1 96 M986A, V988A, TM 12 human MDR1 96 Q990A, V991A V981A, F983A TM 12 human MDR1 96 L975A, F983A TM 12 human MDR1 96 L975A, V981A TM 12 human MDR1 96 F978 TM 12 human MDR1 1 F978A TM 12 human MDR1 25 a aa, amino acid.
X
ABCB1 p.Phe983Ala 11428917:27:1700
status: NEWX
ABCB1 p.Phe983Ala 11428917:27:1705
status: NEWX
ABCB1 p.Phe983Ala 11428917:27:1740
status: NEWX
ABCB1 p.Phe983Ala 11428917:27:1745
status: NEW